Clinical Applications of Serum Tumor Markers
- 15 October 1991
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 115 (8) , 623-638
- https://doi.org/10.7326/0003-4819-115-8-623
Abstract
The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. Tumor markers have five potential uses in patient care: They can be used for screening, for diagnosis, for establishing prognosis, for monitoring treatment, and for detecting relapse. The value of a marker in a given setting depends on two marker-related characteristics--sensitivity and specificity. The value of a marker in a particular malignancy also depends on the effectiveness of therapy for the malignancy. Tumor markers have been used to screen for occult cancer but have proved to be valuable only in selected cancers. As diagnostic tools, tumor markers have limitations: Nearly all markers can be elevated in benign disorders, and most markers are not elevated in the early stages of malignancy. Extreme marker elevation often indicates a poor prognosis and in some malignancies can indicate the need for more aggressive treatment. Tumor markers have their greatest value when used to monitor therapy in patients with widespread cancer. Nearly all markers show some correlation with the clinical course of disease, with marker elevation in any stage declining to normal after a curative intervention. Recurrent disease can be accompanied by increased marker levels, but markers can detect an occult recurrence in only a few diseases, thereby facilitating a second attempt at cure. Although it seems unlikely that an ideal tumor marker will be identified for every malignancy, several workable markers are already available. Increasing our knowledge about the capabilities and limitations of existing markers will enable us to use them judiciously in the treatment of cancer.Keywords
This publication has 196 references indexed in Scilit:
- The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time—II. Prognostic significance in patients treated by chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1990
- Value of neuron specific enolase in early detection of relapse in small cell lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1990
- CA 125 in the diagnosis of pelvic massesEuropean Journal of Cancer and Clinical Oncology, 1989
- Surgery of small hepatocellular carcinoma. Analysis of 144 casesCancer, 1989
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculePublished by Elsevier ,1989
- Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumoursEuropean Journal of Cancer and Clinical Oncology, 1989
- A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancerCancer, 1989
- CA-50 as a tumour marker for monitoring colorectal cancer: Antigen rises in patients postoperatively precede clinical manifestations of recurrenceEuropean Journal of Cancer and Clinical Oncology, 1988
- Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomyEuropean Journal of Cancer and Clinical Oncology, 1987
- Follow-up of colorectal cancer resected for cureDiseases of the Colon & Rectum, 1987